Aurobindo Pharma Limited (NSE: AUROPHARMA)

Aurobindo Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	68,397	33,935	43,963	41,625	53,735	27,637
Short-Term Investments	285.2	29,329	18,364	4,038	2,580	759.1
Trading Asset Securities	-	0.1	0.1	0.1	0.2	0.2
Cash & Short-Term Investments	68,682	63,264	62,327	45,663	56,315	28,396
Cash Growth	-3.93%	1.50%	36.49%	-18.91%	98.32%	45.26%
Accounts Receivable	53,883	48,167	44,664	40,123	35,033	43,152
Other Receivables	-	5,150	5,356	3,619	4,979	4,894
Receivables	54,022	53,446	50,144	43,869	40,155	48,182
Inventory	104,319	98,082	85,112	75,539	90,266	76,999
Other Current Assets	35,234	27,265	17,874	16,157	11,500	10,548
Total Current Assets	262,256	242,056	215,457	181,227	198,235	164,125
Property, Plant & Equipment	149,241	142,849	124,918	106,660	93,155	81,166
Long-Term Investments	2,964	3,216	3,917	6,183	4,312	5,547
Goodwill	6,300	5,952	5,961	4,754	4,289	9,159
Other Intangible Assets	33,786	32,874	31,279	29,587	25,546	23,420
Long-Term Accounts Receivable	1,733	-	-	-	-	-
Long-Term Deferred Tax Assets	12,033	12,126	6,775	2,886	4,527	1,632
Long-Term Deferred Charges	-	1,941	1,980	1,792	1,361	78.2
Other Long-Term Assets	12,571	9,643	8,558	6,065	7,042	4,091
Total Assets	480,945	450,715	398,900	339,217	338,540	289,277
Accounts Payable	44,331	44,542	38,713	27,031	27,947	25,761
Accrued Expenses	-	17,924	16,378	12,165	14,918	19,607
Short-Term Debt	-	41,685	42,304	21,178	48,038	54,223
Current Portion of Long-Term Debt	61,429	117.8	121.3	57.3	-	1,397
Current Portion of Leases	934.3	798.8	1,032	1,599	1,006	1,110
Current Income Taxes Payable	3,636	2,490	2,116	580.3	2,104	950.8
Current Unearned Revenue	-	2,703	3,889	5,679	110.3	10.1
Other Current Liabilities	33,075	11,731	10,385	13,272	12,528	10,788
Total Current Liabilities	143,406	121,991	114,938	81,560	106,651	113,846
Long-Term Debt	19,480	21,349	6,190	2,492	1,685	-
Long-Term Leases	2,430	2,525	3,215	3,186	2,662	2,644
Long-Term Unearned Revenue	-	363.5	-	-	-	-
Long-Term Deferred Tax Liabilities	3,707	3,566	3,896	4,110	5,746	2,917
Other Long-Term Liabilities	3,073	1,665	1,491	1,524	2,052	900
Total Liabilities	172,095	152,207	130,381	93,477	119,250	121,029
Common Stock	580.8	585.9	585.9	585.9	585.9	585.9
Additional Paid-In Capital	-	4,179	4,179	4,179	4,179	4,179
Retained Earnings	-	276,146	247,236	233,322	209,499	158,556
Comprehensive Income & Other	308,203	17,517	16,398	7,674	5,035	4,926
Total Common Equity	308,784	298,428	268,399	245,760	219,299	168,247
Minority Interest	65.7	80	120	-19.3	-8.8	1.4
Shareholders' Equity	308,850	298,508	268,519	245,741	219,290	168,248
Total Liabilities & Equity	480,945	450,715	398,900	339,217	338,540	289,277
Total Debt	84,273	66,476	52,862	28,513	53,391	59,374
Net Cash (Debt)	-15,590	-3,213	9,465	17,150	2,924	-30,977
Net Cash Growth	-	-	-44.81%	486.55%	-	-
Net Cash Per Share	-26.69	-5.48	16.15	29.27	4.99	-52.87
Filing Date Shares Outstanding	583.84	585.94	585.94	585.94	585.94	585.94
Total Common Shares Outstanding	583.84	585.94	585.94	585.94	585.94	585.94
Working Capital	118,851	120,065	100,519	99,667	91,585	50,279
Book Value Per Share	528.88	509.32	458.07	419.43	374.27	287.14
Tangible Book Value	268,698	259,602	231,159	211,419	189,464	135,667
Tangible Book Value Per Share	460.22	443.05	394.51	360.82	323.35	231.54
Land	-	8,686	8,303	6,518	2,860	2,534
Buildings	-	46,978	32,564	25,645	24,177	22,756
Machinery	-	119,040	88,308	76,809	67,543	59,187
Construction In Progress	-	27,394	44,964	29,376	24,289	16,218

Source: S&P Capital IQ. Standard template. Financial Sources.